

# Ming-Sound Tsao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6779123/publications.pdf>

Version: 2024-02-01

556  
papers

61,334  
citations

2093

100  
h-index

1082

232  
g-index

565  
all docs

565  
docs citations

565  
times ranked

63459  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	0.5	4,127
2	Comprehensive genomic characterization of squamous cell lung cancers. Nature, 2012, 489, 519-525.	13.7	3,483
3	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	13.7	3,331
4	The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology, 2015, 10, 1243-1260.	0.5	3,313
5	International network of cancer genome projects. Nature, 2010, 464, 993-998.	13.7	2,114
6	Erlotinib in Lung Cancer â€” Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144.	13.9	1,787
7	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	13.7	1,741
8	Vinorelbine plus Cisplatin vs. Observation in Resected Nonâ€”Small-Cell Lung Cancer. New England Journal of Medicine, 2005, 352, 2589-2597.	13.9	1,737
9	Requirement for glycogen synthase kinase-3Î² in cell survival and NF-Î²B activation. Nature, 2000, 406, 86-90.	13.7	1,346
10	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. Journal of Thoracic Oncology, 2017, 12, 208-222.	0.5	1,067
11	Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898.	13.7	1,020
12	Probability of Cancer in Pulmonary Nodules Detected on First Screening CT. New England Journal of Medicine, 2013, 369, 910-919.	13.9	1,020
13	Gene expressionâ€”based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine, 2008, 14, 822-827.	15.2	1,015
14	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 2009, 41, 1238-1242.	9.4	862
15	Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	0.8	674
16	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
17	EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 49-69.	9.6	644
18	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cellâ€” and patient-derived tumor organoids. Nature Medicine, 2015, 21, 1364-1371.	15.2	591

#	ARTICLE	IF	CITATIONS
19	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	0.5	589
20	DJ-1, a novel regulator of the tumor suppressor PTEN. <i>Cancer Cell</i> , 2005, 7, 263-273.	7.7	495
21	A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma. <i>American Journal of Human Genetics</i> , 2009, 85, 679-691.	2.6	489
22	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature Genetics</i> , 2017, 49, 1126-1132.	9.4	472
23	Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 78-89.	7.7	455
24	Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. <i>Nature Genetics</i> , 2001, 29, 396-403.	9.4	451
25	A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. <i>Nature</i> , 2016, 538, 378-382.	13.7	418
26	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358.	0.5	408
27	Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4417-4424.	0.8	405
28	Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus. <i>PLoS Pathogens</i> , 2011, 7, e1002240.	2.1	404
29	Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. <i>Journal of Clinical Oncology</i> , 2010, 28, 29-34.	0.8	379
30	TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. <i>Genes and Development</i> , 2008, 22, 2677-2691.	2.7	378
31	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3867-3876.	0.8	343
32	ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1101-1110.	13.9	342
33	Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3320-3326.	0.8	327
34	Phase II Study of Temozolomide in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3278-3285.	0.8	321
35	Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7160-7165.	3.3	317
36	Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5240-5247.	0.8	304

#	ARTICLE	IF	CITATIONS
37	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1223-1230.	0.8	300
38	Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype. <i>American Journal of Pathology</i> , 2000, 157, 1623-1631.	1.9	287
39	The Association of Measured Breast Tissue Characteristics with Mammographic Density and Other Risk Factors for Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 343-349.	1.1	283
40	Pooled Analysis of the Prognostic and Predictive Effects of <i>KRAS</i> Mutation Status and <i>KRAS</i> Mutation Subtype in Early-Stage Resected Nonâ€“Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2173-2181.	0.8	270
41	Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3279-3287.	0.8	264
42	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. <i>Cell</i> , 2018, 174, 564-575.e18.	13.5	264
43	Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma. <i>New England Journal of Medicine</i> , 2012, 367, 1417-1427.	13.9	255
44	Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Nonâ€“Small-Cell Lung Cancer Including Stage IA Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 59-64.	0.5	243
45	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. <i>Journal of Thoracic Oncology</i> , 2015, 10, 985-989.	0.5	241
46	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 67-81.	1.3	241
47	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Nonâ€“Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984.	0.8	240
48	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , 2015, 33, 3439-3446.	0.8	234
49	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	0.5	234
50	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
51	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	0.8	229
52	Three-Gene Prognostic Classifier for Early-Stage Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5562-5569.	0.8	226
53	Tumor Mutation Burden as a Biomarker in Resected Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	0.8	223
54	K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. <i>Clinical Lung Cancer</i> , 2006, 8, 30-38.	1.1	212

#	ARTICLE	IF	CITATIONS
55	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 377-407.	0.5	212
56	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	3.6	211
57	Molecular predictive and prognostic markers in non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2009, 10, 1001-1010.	5.1	194
58	Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. <i>Cancer Research</i> , 2002, 62, 3005-8.	0.4	183
59	Prognostic gene signatures for non-small-cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2824-2828.	3.3	182
60	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
61	KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. <i>Oncogene</i> , 2005, 24, 4741-4753.	2.6	167
62	The function of multiple I $\kappa$ B $\epsilon$ : $\kappa$ SNF- $\kappa$ B complexes in the resistance of cancer cells to Taxol-induced apoptosis. <i>Oncogene</i> , 2002, 21, 6510-6519.	2.6	166
63	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 111, 23-29.	0.9	160
64	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1523-1531.	5.1	158
65	Human Papillomavirus-11 DNA in a Patient with Chronic Laryngotracheobronchial Papillomatosis and Metastatic Squamous-Cell Carcinoma of the Lung. <i>New England Journal of Medicine</i> , 1987, 317, 873-878.	13.9	151
66	TRAF6 is an amplified oncogene bridging the RAS and NF- $\kappa$ B pathways in human lung cancer. <i>Journal of Clinical Investigation</i> , 2011, 121, 4095-4105.	3.9	151
67	Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1725-1730.	3.3	150
68	Global Profiling and Molecular Characterization of Alternative Splicing Events Misregulated in Lung Cancer. <i>Molecular and Cellular Biology</i> , 2011, 31, 138-150.	1.1	149
69	The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. <i>Nature Methods</i> , 2014, 11, 585-592.	9.0	149
70	Quantitative image analysis of immunohistochemical stains using a CMYK color model. <i>Diagnostic Pathology</i> , 2007, 2, 8.	0.9	148
71	Organoid Cultures as Preclinical Models of Non- $\epsilon$ Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1162-1174.	3.2	148
72	The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non- $\epsilon$ Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 134-141.	3.2	147

#	ARTICLE	IF	CITATIONS
73	Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 1992, 16, 259-268.	2.1	144
74	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. <i>Cancer</i> , 2010, 116, 5599-5607.	2.0	143
75	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019, 10, 278.	5.8	143
76	Integrin $\alpha$ 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 11754-11759.	3.3	141
77	Class III $\beta$ -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10. <i>Clinical Cancer Research</i> , 2007, 13, 994-999.	3.2	138
78	Genomic DNA functions as a universal external standard in quantitative real-time PCR. <i>Nucleic Acids Research</i> , 2006, 34, e85-e85.	6.5	137
79	Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 823-829.	0.4	136
80	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	2.9	135
81	Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma. <i>American Journal of Pathology</i> , 1998, 153, 263-269.	1.9	131
82	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. <i>Journal of Clinical Investigation</i> , 2010, 120, 3296-3309.	3.9	129
83	HDL-Mimicking Peptide-Lipid Nanoparticles with Improved Tumor Targeting. <i>Small</i> , 2010, 6, 430-437.	5.2	122
84	Optimization of miRNA-seq data preprocessing. <i>Briefings in Bioinformatics</i> , 2015, 16, 950-963.	3.2	120
85	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 1379-1388.	5.1	119
86	Robust global microRNA expression profiling using next-generation sequencing technologies. <i>Laboratory Investigation</i> , 2014, 94, 350-358.	1.7	118
87	A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The SMART Approach for Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 397-402.	0.5	117
88	Identification of 27 CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. <i>Oncogene</i> , 2004, 23, 8705-8710.	2.6	115
89	TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 797-802.	3.3	113
90	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 334-346.	0.5	113

#	ARTICLE	IF	CITATIONS
91	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1210-1222.	0.5	112
92	Refined RIP-seq protocol for epitranscriptome analysis with low input materials. <i>PLoS Biology</i> , 2018, 16, e2006092.	2.6	112
93	Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. <i>Lung Cancer</i> , 1998, 20, 1-16.	0.9	111
94	In vitro Modeling of Human Pancreatic Duct Epithelial Cell Transformation Defines Gene Expression Changes Induced by K-ras Oncogenic Activation in Pancreatic Carcinogenesis. <i>Cancer Research</i> , 2005, 65, 5045-5053.	0.4	110
95	Autotaxin Expression in Non-Small-Cell Lung Cancer. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 21, 216-222.	1.4	109
96	Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , 2000, 190, 150-156.		107
97	Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1219-1220.	0.8	107
98	Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1653-1660.	0.5	107
99	Programmed Death Ligand-1 Immunohistochemistry: A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 341-344.	1.2	107
100	Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience. <i>Lung Cancer</i> , 2010, 67, 177-183.	0.9	106
101	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106
102	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. <i>Journal of Thoracic Oncology</i> , 2006, 1, S13-S19.	0.5	106
103	KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 530-542.	0.5	104
104	Epithelial-Cadherin and $\beta$ -Catenin Expression Changes in Pancreatic Intraepithelial Neoplasia. <i>Clinical Cancer Research</i> , 2004, 10, 1235-1240.	3.2	101
105	A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5526-5533.	3.2	99
106	Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. <i>Modern Pathology</i> , 2012, 25, 758-766.	2.9	99
107	Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes. <i>Molecular Cancer Research</i> , 2017, 15, 3-14.	1.5	98
108	Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. <i>Modern Pathology</i> , 2008, 21, 817-825.	2.9	97

#	ARTICLE	IF	CITATIONS
109	Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3316-3322.	0.8	96
110	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1267-1272.	1.2	95
111	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i> -Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2472-2480.	0.8	94
112	Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 6229-6236.	0.8	93
113	Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. <i>Nature Communications</i> , 2014, 5, 5469.	5.8	93
114	The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through $\beta_2$ -adrenergic transactivation of EGF receptors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 639-648.	1.2	92
115	KIF14 Messenger RNA Expression Is Independently Prognostic for Outcome in Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3229-3234.	3.2	92
116	Pooled Analysis of the Prognostic and Predictive Effects of <i>TP53</i> Comutation Status Combined With <i>KRAS</i> or <i>EGFR</i> Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2018-2027.	0.8	91
117	Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor $\beta_1$ and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer. <i>Cancer Research</i> , 2009, 69, 4517-4526.	0.4	90
118	Novel candidate tumor marker genes for lung adenocarcinoma. <i>Oncogene</i> , 2002, 21, 7598-7604.	2.6	89
119	A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1379-1391.	0.5	89
120	Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma. <i>PLoS Medicine</i> , 2010, 7, e1000315.	3.9	87
121	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 344-359.	0.5	87
122	Keratinocyte Growth Factor/Fibroblast Growth Factor-7-regulated Cell Migration and Invasion through Activation of NF- $\kappa$ B Transcription Factors. <i>Journal of Biological Chemistry</i> , 2007, 282, 6001-6011.	1.6	86
123	Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients. <i>Lung Cancer</i> , 2016, 92, 53-61.	0.9	86
124	Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. <i>Cancer Cell</i> , 2021, 39, 1115-1134.e12.	7.7	86
125	Pathogenesis of pulmonary infarction. <i>American Journal of Medicine</i> , 1982, 72, 599-606.	0.6	85
126	Cost Effectiveness of <i>EML4-ALK</i> Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1012-1019.	0.8	85



#	ARTICLE	IF	CITATIONS
127	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
128	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 135, 184-189.	0.6	84
129	FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. <i>Journal of Clinical Pathology</i> , 2010, 63, 630-634.	1.0	83
130	Expression of Active Protein Kinase B in T Cells Perturbs Both T and B Cell Homeostasis and Promotes Inflammation. <i>Journal of Immunology</i> , 2001, 167, 42-48.	0.4	80
131	Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein. <i>Cancer Research</i> , 2013, 73, 1934-1945.	0.4	80
132	Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker. <i>Clinical Cancer Research</i> , 2004, 10, 1984-1991.	3.2	79
133	Malignant mesothelioma in situ: morphologic features and clinical outcome. <i>Modern Pathology</i> , 2020, 33, 297-302.	2.9	79
134	Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. <i>PLoS ONE</i> , 2017, 12, e0177875.	1.1	79
135	Dysregulated PTEN-PKB and negative receptor status in human breast cancer. <i>International Journal of Cancer</i> , 2003, 104, 195-203.	2.3	78
136	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 850-861.	0.5	78
137	ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , 2017, 18, 156-161.	1.1	78
138	Phase II study of PX-866 in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1270-4.	0.6	77
139	p53 gene mutations in human endometrial carcinoma. <i>Molecular Carcinogenesis</i> , 1992, 5, 250-253.	1.3	76
140	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations. <i>Clinical Lung Cancer</i> , 2006, 7, S138-S144.	1.1	76
141	The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1. <i>Cancer Cell</i> , 2014, 25, 181-195.	7.7	76
142	Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method. <i>The Lancet Digital Health</i> , 2019, 1, e353-e362.	5.9	76
143	Primary pulmonary adenocarcinoma with enteric differentiation. <i>Cancer</i> , 1991, 68, 1754-1757.	2.0	75
144	Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. <i>Molecular Carcinogenesis</i> , 2005, 43, 215-224.	1.3	75

#	ARTICLE	IF	CITATIONS
145	The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head &amp; Neck Oncology</i> , 2011, 3, 11.	2.3	75
146	A review of erlotinib and its clinical use. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 177-193.	0.9	74
147	Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e71670.	1.1	74
148	Optimized application of penalized regression methods to diverse genomic data. <i>Bioinformatics</i> , 2011, 27, 3399-3406.	1.8	73
149	Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1255-1263.	0.5	73
150	Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing. <i>Journal of Thoracic Oncology</i> , 2014, 9, 947-956.	0.5	72
151	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 408-419.	1.2	70
152	ras mutation and expression of theras-regulated genes osteopontin and cathepsin L in human esophageal cancer. , 1997, 72, 739-745.		69
153	A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. <i>Cancer Cell</i> , 2015, 28, 623-637.	7.7	68
154	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	0.5	68
155	UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium. <i>Gynecologic Oncology</i> , 2007, 106, 305-310.	0.6	67
156	Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. <i>BMC Cancer</i> , 2010, 10, 285.	1.1	67
157	Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. <i>International Journal of Cancer</i> , 2017, 140, 662-673.	2.3	67
158	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. <i>Nature Communications</i> , 2019, 10, 224.	5.8	66
159	Role of myofibroblasts in innate chemoresistance of pancreatic carcinomaâ€”Epigenetic downregulation of caspases. <i>International Journal of Cancer</i> , 2008, 123, 1751-1760.	2.3	64
160	Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10155-10160.	3.3	64
161	Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 298-306.	3.0	64
162	Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e46677.	1.1	64

#	ARTICLE	IF	CITATIONS
163	The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. <i>Journal of Thoracic Oncology</i> , 2022, 17, 608-622.	0.5	64
164	Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 527-529.	0.5	63
165	Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 139-147.	0.5	63
166	Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?. <i>European Respiratory Journal</i> , 2014, 44, 1011-1022.	3.1	63
167	Recapitulating Pancreatic Tumor Microenvironment through Synergistic Use of Patient Organoids and Organ-on-a-Chip Vasculature. <i>Advanced Functional Materials</i> , 2020, 30, 2000545.	7.8	62
168	Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells. <i>Neoplasia</i> , 2009, 11, 1292-IN6.	2.3	61
169	A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 609-613.	0.6	61
170	Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1798-1809.	0.5	61
171	Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. <i>Oncogene</i> , 2005, 24, 4806-4812.	2.6	60
172	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. <i>Nature Communications</i> , 2018, 9, 3221.	5.8	60
173	Co-expression of epidermal growth factor receptor and transforming growth factor- $\beta$ is independent of ras mutations in lung adenocarcinoma. <i>Lung Cancer</i> , 2000, 29, 151-157.	0.9	59
174	Understanding Prognostic Gene Expression Signatures in Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 331-340.	1.1	59
175	Genes and Pathology of Non-Small Cell Lung Carcinoma. <i>Seminars in Oncology</i> , 2014, 41, 28-39.	0.8	59
176	Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. <i>Modern Pathology</i> , 2008, 21, 271-281.	2.9	58
177	Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts. <i>Cancers</i> , 2014, 6, 459-471.	1.7	57
178	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014, 35, 1267-1275.	1.3	57
179	Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development. <i>PLoS ONE</i> , 2012, 7, e37775.	1.1	56
180	Tight junction protein zo-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. , 1999, 82, 137-144.		55

#	ARTICLE	IF	CITATIONS
181	Characterization of collagen in non-small cell lung carcinoma with second harmonic polarization microscopy. <i>Biomedical Optics Express</i> , 2014, 5, 3562.	1.5	55
182	Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1521-1529.	0.5	54
183	Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. <i>Carcinogenesis</i> , 2008, 29, 647-655.	1.3	53
184	Activation of Hepatocyte Growth Factor-Met Autocrine Loop Enhances Tumorigenicity in a Human Lung Adenocarcinoma Cell Line. <i>Neoplasia</i> , 2000, 2, 226-234.	2.3	52
185	Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. <i>BMC Cancer</i> , 2008, 8, 43.	1.1	52
186	Identification of Novel Lung Genes in Bronchial Epithelium by Serial Analysis of Gene Expression. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 35, 651-661.	1.4	51
187	Plasma Transforming Growth Factor $\beta$ and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21. <i>Journal of Clinical Oncology</i> , 2010, 28, 5247-5256.	0.8	51
188	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006596.	1.5	51
189	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2214-2232.	1.3	51
190	Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2016, 11, 312-323.	0.5	50
191	Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PivOTAL observational study. <i>PLoS ONE</i> , 2018, 13, e0202865.	1.1	50
192	Characterization of Human Bronchial Epithelial Cells Immortalized by the E6 and E7 Genes of Human Papillomavirus Type 16. <i>Experimental Cell Research</i> , 1994, 212, 36-41.	1.2	49
193	Grg1 Acts as a Lung-Specific Oncogene in a Transgenic Mouse Model. <i>Cancer Research</i> , 2006, 66, 1294-1301.	0.4	49
194	LOXL1 Is Regulated by Integrin $\alpha$ 11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity. <i>Cancers</i> , 2019, 11, 705.	1.7	49
195	Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. <i>Human Pathology</i> , 2001, 32, 57-65.	1.1	48
196	Adoptive immunotherapy of cancer using ex vivo expanded human $\gamma\delta$ T cells: A new approach. <i>Cancer Letters</i> , 2010, 297, 126-136.	3.2	48
197	L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1914-1924.	3.2	48
198	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2499-2505.	3.2	48

#	ARTICLE	IF	CITATIONS
199	Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. <i>Human Pathology</i> , 2006, 37, 212-217.	1.1	47
200	Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 253-259.	1.1	47
201	Inhibition of proliferation of cultured rat liver epithelial cells at specific cell cycle stages by transforming growth factor- $\beta$ . <i>Biochemical and Biophysical Research Communications</i> , 1987, 143, 26-30.	1.0	46
202	Detection of <i>EGFR</i> and <i>KRAS</i> mutations in fine-needle aspirates stored on Whatman FTA cards. <i>Cancer Cytopathology</i> , 2010, 118, 450-456.	1.4	46
203	Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1513-1521.	0.5	46
204	Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12101-12108.	3.3	46
205	SOX15 and other SOX family members are important mediators of tumorigenesis in multiple cancer types.. <i>Oncoscience</i> , 2014, 1, 326-335.	0.9	46
206	Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma. <i>Molecular Cancer</i> , 2010, 9, 24.	7.9	45
207	<i>NKG2D</i> regulates production of soluble <i>TRAIL</i> by ex vivo expanded human <i>T</i> cells. <i>European Journal of Immunology</i> , 2013, 43, 3175-3182.	1.6	45
208	Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1449-1458.	0.5	45
209	Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. <i>Chest</i> , 2016, 150, 1015-1022.	0.4	45
210	High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 308-313.	1.5	44
211	Abelson Interactor Protein-1 Positively Regulates Breast Cancer Cell Proliferation, Migration, and Invasion. <i>Molecular Cancer Research</i> , 2007, 5, 1031-1039.	1.5	44
212	Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1101-1108.	0.5	44
213	Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 1060-1067.	3.2	44
214	Autocrine Growth Loop of The Epidermal Growth Factor Receptor in Normal and Immortalized Human Bronchial Epithelial Cells. <i>Experimental Cell Research</i> , 1996, 223, 268-273.	1.2	43
215	Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. <i>Lung Cancer</i> , 2004, 46, 197-204.	0.9	43
216	Stability and Heterogeneity of Expression Profiles in Lung Cancer Specimens Harvested Following Surgical Resection. <i>Neoplasia</i> , 2004, 6, 761-767.	2.3	43

#	ARTICLE	IF	CITATIONS
217	CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration. <i>Molecular Cancer Research</i> , 2015, 13, 1119-1129.	1.5	43
218	Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 195-202.	0.3	43
219	Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. <i>Nature Communications</i> , 2018, 9, 3927.	5.8	43
220	Brca2 Deficiency Does Not Impair Mammary Epithelium Development but Promotes Mammary Adenocarcinoma Formation in p53+/âˆ™ Mutant Mice. <i>Cancer Research</i> , 2004, 64, 1959-1965.	0.4	42
221	A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. <i>Clinical Colorectal Cancer</i> , 2018, 17, 231-239.e7.	1.0	42
222	Prognostic markers in lung cancer: is it ready for prime time?. <i>Translational Lung Cancer Research</i> , 2014, 3, 149-58.	1.3	42
223	A sequence-based approach to identify reference genes for gene expression analysis. <i>BMC Medical Genomics</i> , 2010, 3, 32.	0.7	41
224	Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: Review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. <i>Lung Cancer</i> , 2012, 77, 501-506.	0.9	41
225	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3431-3442.	3.2	41
226	Malignant rhabdoid tumor of the colon. <i>Diseases of the Colon and Rectum</i> , 1996, 39, 1322-1326.	0.7	40
227	Induction chemoradiotherapy facilitates radical resection of T4 nonâ€™small cell lung cancer invading the spine. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 441-447.e1.	0.4	40
228	Regulation of pancreatic cancer growth by superoxide. <i>Molecular Carcinogenesis</i> , 2013, 52, 555-567.	1.3	40
229	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1037-1053.	0.5	40
230	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 136-151.	0.9	40
231	Activation of murine kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. <i>Hepatology</i> , 1988, 8, 1046-1050.	3.6	39
232	Overexpression of G1-S Cyclins and Cyclin-Dependent Kinases during Multistage Human Pancreatic Duct Cell Carcinogenesis. <i>Clinical Cancer Research</i> , 2004, 10, 6598-6605.	3.2	39
233	Interaction between <i>MYC</i> and <i>MCL1</i> in the Genesis and Outcome of Nonâ€™Small-Cell Lung Cancer. <i>Cancer Research</i> , 2011, 71, 2212-2221.	0.4	39
234	Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. <i>Oncotarget</i> , 2016, 7, 33571-33580.	0.8	39

#	ARTICLE	IF	CITATIONS
235	Expression of Chicken Ovalbumin Upstream Promoter-Transcription Factor II Enhances Invasiveness of Human Lung Carcinoma Cells. <i>Cancer Research</i> , 2004, 64, 5097-5105.	0.4	38
236	Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 109-116.	1.1	38
237	Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. <i>Journal of Immunology</i> , 2019, 7, 17.		38
238	Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. <i>Cancer Research</i> , 2002, 62, 6194-204.	0.4	38
239	Establishment of propagable epithelial cell lines from normal adult rat pancreas. <i>Experimental Cell Research</i> , 1987, 168, 365-375.	1.2	37
240	Large fragment Bst DNA polymerase for whole genome amplification of DNA from formalin-fixed paraffin-embedded tissues. <i>BMC Genomics</i> , 2006, 7, 312.	1.2	37
241	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1663-1669.	0.5	37
242	Long-Term Outcome after En Bloc Resection of Non-Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1538-1544.	0.5	36
243	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 699-714.	0.6	36
244	SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis. <i>PLoS Biology</i> , 2016, 14, e1002581.	2.6	35
245	TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2017, 7, 39692.	1.6	35
246	Human Pancreatic Duct Epithelial Cell Model for KRAS Transformation. <i>Methods in Enzymology</i> , 2008, 439, 1-13.	0.4	34
247	Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1354-1362.	0.5	34
248	Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. <i>Cancer Research</i> , 2019, 79, 4539-4550.	0.4	34
249	Predicting Malignancy Risk of Screen-Detected Lung Nodules—Mean Diameter or Volume. <i>Journal of Thoracic Oncology</i> , 2019, 14, 203-211.	0.5	34
250	Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways. <i>Cancers</i> , 2020, 12, 2071.	1.7	34
251	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 190-197.	5.1	34
252	A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 963-972.	0.5	33

#	ARTICLE	IF	CITATIONS
253	Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1172-1180.	0.5	33
254	Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. <i>Modern Pathology</i> , 2020, 33, 281-296.	2.9	33
255	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non-Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. <i>Clinical Lung Cancer</i> , 2014, 15, 52-57.	1.1	32
256	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1864-1888.	2.5	32
257	Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. <i>BMJ Open</i> , 2019, 9, e024719.	0.8	32
258	Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 123.	3.5	32
259	Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. <i>Oncogene</i> , 2004, 23, 6316-6324.	2.6	31
260	Ethanol and the Tobacco-specific Carcinogen, NNK, Contribute to Signaling in Immortalized Human Pancreatic Duct Epithelial Cells. <i>Pancreas</i> , 2006, 33, 53-62.	0.5	31
261	Prognostic Gene Expression Signature for Squamous Cell Carcinoma of Lung. <i>Clinical Cancer Research</i> , 2010, 16, 5038-5047.	3.2	31
262	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67876.	1.1	31
263	Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor. <i>Scientific Reports</i> , 2020, 10, 14514.	1.6	31
264	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020, 11, 2220.	5.8	31
265	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	0.9	31
266	Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. <i>Lung Cancer</i> , 2013, 79, 215-220.	0.9	30
267	PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2014, 9, 239-247.	0.5	30
268	Plasma pro-surfactant protein B and lung function decline in smokers. <i>European Respiratory Journal</i> , 2015, 45, 1037-1045.	3.1	30
269	Computer Vision Tool and Technician as First Reader of Lung Cancer Screening CT Scans. <i>Journal of Thoracic Oncology</i> , 2016, 11, 709-717.	0.5	30
270	Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion. <i>Neoplasia</i> , 2019, 21, 482-493.	2.3	30



#	ARTICLE	IF	CITATIONS
271	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 64-77.	1.9	30
272	A drug discovery platform to identify compounds that inhibit EGFR triple mutants. <i>Nature Chemical Biology</i> , 2020, 16, 577-586.	3.9	30
273	Polarimetric second-harmonic generation microscopy of the hierarchical structure of collagen in stage III non-small cell lung carcinoma. <i>Biomedical Optics Express</i> , 2020, 11, 1851.	1.5	30
274	Loss of Canonical Smad4 Signaling Promotes KRAS Driven Malignant Transformation of Human Pancreatic Duct Epithelial Cells and Metastasis. <i>PLoS ONE</i> , 2013, 8, e84366.	1.1	30
275	Expression of Kallikrein-Related Peptidase 7 Predicts Poor Prognosis in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1135-1142.	1.1	29
276	Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 235-241.	0.9	29
277	Synergy of WEE1 and mTOR Inhibition in Mutant <i>KRAS</i> -Driven Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 6993-7005.	3.2	29
278	The effects of epidermal growth factor and the state of confluence on enzymatic activities of cultured rat liver epithelial cells. <i>Journal of Cellular Physiology</i> , 1986, 126, 167-173.	2.0	28
279	zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. , 1999, 83, 349-358.		28
280	Epidermal Growth Factor Receptor Biomarkers in Non-Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma. <i>Journal of Clinical Oncology</i> , 2010, 28, 903-905.	0.8	28
281	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	3.4	28
282	The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 22-29.	0.9	28
283	Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2082-2091.e1.	0.4	28
284	Regulation of growth of cultured hepatic epithelial cells by transferrin. <i>Experimental Cell Research</i> , 1987, 171, 52-62.	1.2	27
285	Cigarette smoke components inhibited intercellular communication and differentiation in human pancreatic ductal epithelial cells. <i>International Journal of Cancer</i> , 2007, 120, 1855-1862.	2.3	27
286	Primary Tumor Xenografts of Human Lung Adeno and Squamous Cell Carcinoma Express Distinct Proteomic Signatures. <i>Journal of Proteome Research</i> , 2011, 10, 161-174.	1.8	27
287	Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 3200-3211.	1.8	27
288	Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1371-1377.	0.5	27

#	ARTICLE	IF	CITATIONS
289	Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 900-909.	0.5	27
290	Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway. <i>Nutrients</i> , 2018, 10, 1289.	1.7	27
291	Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1281-1284.	1.2	26
292	The role of FOXOs and autophagy in cancer and metastasis—Implications in therapeutic development. <i>Medicinal Research Reviews</i> , 2020, 40, 2089-2113.	5.0	26
293	Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1490-1500.	0.5	26
294	A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, e200-e202.	0.5	25
295	Early innate and adaptive immune perturbations determine long-term severity of chronic virus and <i>Mycobacterium tuberculosis</i> coinfection. <i>Immunity</i> , 2021, 54, 526-541.e7.	6.6	25
296	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. <i>Pathology</i> , 2021, 53, 446-453.	0.3	25
297	Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. <i>Laboratory Investigation</i> , 2013, 93, 397-407.	1.7	24
298	Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches. <i>Proteomics</i> , 2014, 14, 795-803.	1.3	24
299	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020, 146, 78-85.	0.9	24
300	Transcriptome Profiles of Carcinoma-in-Situ and Invasive Non-Small Cell Lung Cancer as Revealed by SAGE. <i>PLoS ONE</i> , 2010, 5, e9162.	1.1	23
301	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1830-1844.	0.5	23
302	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. <i>Journal of Thoracic Oncology</i> , 2014, 9, 141-143.	0.5	23
303	CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9502-9502.	0.8	23
304	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. <i>Oncotarget</i> , 2017, 8, 69651-69662.	0.8	23
305	Absence of Caspase-3 Protects Pancreatic $\beta$ -Cells from c-Myc-induced Apoptosis without Leading to Tumor Formation. <i>Journal of Biological Chemistry</i> , 2009, 284, 10947-10956.	1.6	22
306	Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma. <i>Histopathology</i> , 2014, 64, 826-839.	1.6	22

#	ARTICLE	IF	CITATIONS
307	Molecular testing in stage III non-small cell lung cancer: Approaches and challenges. <i>Lung Cancer</i> , 2021, 162, 42-53.	0.9	22
308	Expression profiling by microarrays in colorectal cancer (Review). <i>Oncology Reports</i> , 0, , .	1.2	22
309	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. <i>Nature Communications</i> , 2021, 12, 6274.	5.8	22
310	A Study of Smoking, p53 Tumor Suppressor Gene Alterations and Non-Small Cell Lung Cancer. <i>Annals of Epidemiology</i> , 2000, 10, 176-185.	0.9	21
311	Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 935-942.	1.1	21
312	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	0.5	21
313	Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers. <i>PLoS ONE</i> , 2015, 10, e0121872.	1.1	21
314	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. <i>Nature Communications</i> , 2022, 13, 1811.	5.8	21
315	Sequential Changes in Epidermal Growth Factor Receptor/Ligand Function in Cultured Rat Liver Epithelial Cells Transformed Chemically in vitro. <i>Pathobiology</i> , 1990, 58, 3-14.	1.9	20
316	In Compressed Lung Tissue Microscopic Sections of Adenocarcinoma In Situ May Mimic Papillary Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1792-1797.	1.2	20
317	Genomic Testing in Lung Cancer: Past, Present, and Future. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 323-334.	2.3	20
318	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018, 9, 22559-22570.	0.8	20
319	SHORT COMMUNICATION. <i>Carcinogenesis</i> , 1986, 7, 669-671.	1.3	19
320	Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. <i>Lung Cancer</i> , 2003, 41, 91-99.	0.9	19
321	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 66-73.e6.	1.1	19
322	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020, 143, 1-11.	0.9	19
323	Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1328-1337.	0.5	19
324	Introduction to 2021 WHO Classification of Thoracic Tumors. <i>Journal of Thoracic Oncology</i> , 2022, 17, e1-e4.	0.5	19

#	ARTICLE	IF	CITATIONS
325	Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefits in an Orthotopic Human Non-small Cell Lung Cancer Model. <i>Journal of Thoracic Oncology</i> , 2006, 1, 771-779.	0.5	18
326	Defining Genomic Alteration Boundaries for a Combined Small Cell and Non-small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 227-239.	0.5	18
327	Association of the 15q25 and 5p15 Lung Cancer Susceptibility Regions with Gene Expression in Lung Tumor Tissue. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1097-1104.	1.1	18
328	Cancer proteome and metabolite changes linked to SHMT2. <i>PLoS ONE</i> , 2020, 15, e0237981.	1.1	18
329	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020, 33, 1874-1888.	2.9	18
330	A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG) Tj ETQq0 0 0 rgBT /Overlock 10 10.50 537 16 (IND.229	1.5	18
331	Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. <i>Lung Cancer</i> , 2015, 89, 110-114.	0.9	17
332	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, 73-79.	1.0	17
333	Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5990-6000.	3.2	17
334	Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Disease</i> , 2015, 7, 1898-906.	0.6	17
335	grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten+/- mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15358-15363.	3.3	16
336	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , 2020, 26, 2477-2486.	3.2	16
337	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. <i>Cell Reports</i> , 2021, 34, 108707.	2.9	16
338	Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 127-135.	0.9	16
339	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11002-11002.	0.8	16
340	Hepatic Sinusoidal Fibrosis in Agnogenic Myeloid Metaplasia. <i>American Journal of Clinical Pathology</i> , 1989, 91, 302-305.	0.4	15
341	Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 85-90.	2.0	15
342	C/EBPβ mutations in lung cancer. <i>Lung Cancer</i> , 2006, 53, 253-254.	0.9	15

#	ARTICLE	IF	CITATIONS
343	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. <i>Genome Medicine</i> , 2012, 4, 84.	3.6	15
344	p120RasGAP Is a Mediator of Rho Pathway Activation and Tumorigenicity in the DLD1 Colorectal Cancer Cell Line. <i>PLoS ONE</i> , 2014, 9, e86103.	1.1	15
345	A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 607-611.	1.0	15
346	Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2020, 39, 308-321.	2.6	15
347	A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 1077-1084.	1.2	15
348	Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 276-284.	0.9	15
349	Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. <i>Scientific Reports</i> , 2021, 11, 10619.	1.6	15
350	Ancillary Testing in Lung Cancer Diagnosis. <i>Pulmonary Medicine</i> , 2012, 2012, 1-8.	0.5	14
351	Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients. <i>Cancer Immunology Research</i> , 2017, 5, 821-829.	1.6	14
352	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing. <i>Cancer</i> , 2019, 125, 4043-4051.	2.0	14
353	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 32-39.	0.9	14
354	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e338-e345.	1.1	14
355	Implementation of PD-L1 22C3 IHC pharmDx™;TM™; in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation. <i>Acta Cytologica</i> , 2020, 64, 577-587.	0.7	14
356	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020, 146, 350-354.	0.9	14
357	Abstract 4360: Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer. , 2018, , .		14
358	Annulate Lamellae in a Large Cell Lung Carcinoma Cell Line with High Expression of Tyrosine Kinase Receptor and Proto-Oncogenes. <i>Ultrastructural Pathology</i> , 1992, 16, 439-449.	0.4	13
359	Dissociation of Gemcitabine Sensitivity and Protein Kinase B Signaling in Pancreatic Ductal Adenocarcinoma Models. <i>Pancreas</i> , 2007, 35, e16-e26.	0.5	13
360	Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung. <i>Clinical Cancer Research</i> , 2015, 21, 1477-1486.	3.2	13

#	ARTICLE	IF	CITATIONS
361	Anti-PD-1-associated organizing pneumonia in a responding melanoma patient. <i>Annals of Oncology</i> , 2016, 27, 1649-1650.	0.6	13
362	Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes. <i>Oncotarget</i> , 2018, 9, 9137-9155.	0.8	13
363	PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC. <i>Scientific Reports</i> , 2019, 9, 12437.	1.6	13
364	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
365	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017, 8, 84659-84670.	0.8	13
366	Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/ $\hat{a}$ mice. <i>Gynecologic Oncology</i> , 2008, 108, 395-401.	0.6	12
367	Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. <i>Clinical Lung Cancer</i> , 2016, 17, 375-383.e2.	1.1	12
368	Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. <i>BMC Pulmonary Medicine</i> , 2020, 20, 300.	0.8	12
369	Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis. <i>American Journal of Clinical Pathology</i> , 2021, 156, 989-999.	0.4	12
370	Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System. <i>Current Oncology</i> , 2021, 28, 3268-3279.	0.9	12
371	Cauda Equina Paraganglioma. <i>Canadian Journal of Neurological Sciences</i> , 1983, 10, 266-269.	0.3	11
372	National Working Group Meeting on ALK diagnostics in lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 11-17.	0.7	11
373	A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 84, 289-294.	0.9	11
374	Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium. <i>PLoS ONE</i> , 2017, 12, e0185660.	1.1	11
375	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 416-427.	1.3	11
376	CD45+CD326+ Cells are Predictive of Poor Prognosis in Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6756-6763.	3.2	11
377	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1228-1237.	1.1	11
378	Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1003-1011.	0.5	11

#	ARTICLE	IF	CITATIONS
379	Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. <i>Translational Oncology</i> , 2021, 14, 101179.	1.7	11
380	Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 277-288.	0.5	11
381	Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1966-1978.	3.2	11
382	Modified gateway system for double shRNA expression and Cre/lox based gene expression. <i>BMC Biotechnology</i> , 2011, 11, 24.	1.7	10
383	Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. <i>Laboratory Investigation</i> , 2018, 98, 403-413.	1.7	10
384	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , 2019, 130, 135-142.	0.9	10
385	Old Soldiers Never Die: Is There Still a Role for Immunohistochemistry in the Era of Next-Generation Sequencing Panel Testing?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2035-2038.	0.5	10
386	Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 205.	1.7	10
387	Biochemical effects of 12-O-tetradecanoylphorbol-13-acetate, retinoic acid, phenobarbital, and 5-azacytidine on a normal rat liver epithelial cell line. <i>Journal of Cellular Physiology</i> , 1984, 121, 1-6.	2.0	9
388	Glutathione and glutathione S-transferases in clones of cultured rat liver epithelial cells that express varying activity of $\beta$ -glutamyl transpeptidase. <i>Molecular Carcinogenesis</i> , 1989, 2, 144-149.	1.3	9
389	Effect of proliferative state on glutathione S-transferase isoenzyme in cultured rat liver epithelial cells. <i>Carcinogenesis</i> , 1991, 12, 2031-2034.	1.3	9
390	Peptide differential display of serum-free conditioned medium from cancer cell lines. <i>Cancer Letters</i> , 2002, 176, 199-203.	3.2	9
391	Differential utilization of NF-kappaB RELA and RELB in response to extracellular versus intracellular polyIC stimulation in HT1080 cells. <i>BMC Immunology</i> , 2011, 12, 15.	0.9	9
392	Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 438-445.	1.2	9
393	Multiplexed Real-Time NMR GTPase Assay for Simultaneous Monitoring of Multiple Guanine Nucleotide Exchange Factor Activities from Human Cancer Cells and Organoids. <i>Journal of the American Chemical Society</i> , 2018, 140, 4473-4476.	6.6	9
394	Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 236-265.	0.2	9
395	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. <i>JCO Precision Oncology</i> , 2020, 4, 520-533.	1.5	9
396	Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7007-7007.	0.8	9

#	ARTICLE	IF	CITATIONS
397	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the OncoPrint Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2620.	0.8	9
398	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 25632-25639.	0.8	9
399	Integrin $\alpha 11 \beta 21$ in tumor fibrosis: more than just another cancer-associated fibroblast biomarker?. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 649-660.	1.8	9
400	Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy. , 2015, , .		8
401	BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2460-2470.	3.2	8
402	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.	0.5	8
403	Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. <i>Pharmaceuticals</i> , 2020, 13, 289.	1.7	8
404	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. <i>Journal of Thoracic Oncology</i> , 2021, 16, 897-901.	0.5	8
405	Risk Perception Among a Lung Cancer Screening Population. <i>Chest</i> , 2021, 160, 718-730.	0.4	8
406	The modulation of growth of normal rat liver epithelial cells in calcium-poor medium by epidermal growth factor, phenobarbital, phorbol ester, and retinoic acid. <i>In Vitro</i> , 1985, 21, 249-253.	1.2	7
407	Regulation by epidermal growth factor of the expression of transforming growth factor- $\beta 21$ mRNA in cultured rat liver epithelial cells. <i>Experimental Cell Research</i> , 1991, 195, 214-217.	1.2	7
408	High Expression of Met/Hepatocyte Growth Factor Receptor Suppresses Tumorigenicity in NCI-H1264 Lung Carcinoma Cells. <i>Experimental Cell Research</i> , 2002, 273, 45-53.	1.2	7
409	Re: Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1677-1678.	3.0	7
410	ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. <i>Cancer Epidemiology</i> , 2016, 41, 50-56.	0.8	7
411	HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, 422-424.	0.5	7
412	Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. <i>Genetic Epidemiology</i> , 2021, 45, 99-114.	0.6	7
413	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. <i>Lung Cancer</i> , 2021, 156, 76-81.	0.9	7
414	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 57528-57536.	0.8	7



#	ARTICLE	IF	CITATIONS
415	Induction of gamma-glutamyl transpeptidase activity by all-trans retinoic acid in cultured rat liver epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 157, 1039-1045.	1.0	6
416	Applications of Array-CGH for Lung Cancer. <i>Methods in Molecular Biology</i> , 2013, 973, 297-324.	0.4	6
417	Forty Years of the International Association for Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1740-1749.	0.5	6
418	Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials. <i>Clinical Cancer Research</i> , 2016, 22, PR03-PR03.	3.2	6
419	Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11585-11585.	0.8	6
420	Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5522-5522.	0.8	6
421	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110563.	1.4	6
422	Inconsistent effects of all-trans retinoic acid on different clones of chemically transformed rat liver epithelial cells. <i>Carcinogenesis</i> , 1987, 8, 497-501.	1.3	5
423	Should Mutational Analyses of Tumor Samples Bypass Histopathology?. <i>Journal of Thoracic Oncology</i> , 2007, 2, 375-376.	0.5	5
424	Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. <i>Carcinogenesis</i> , 2019, 40, 432-440.	1.3	5
425	PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry. <i>Lung Cancer</i> , 2020, 148, 55-61.	0.9	5
426	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020, 21, e488-e492.	1.1	5
427	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 826-838.	1.3	5
428	Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6041-6041.	0.8	5
429	Assessing therapy response in patient-derived xenografts. <i>Science Translational Medicine</i> , 2021, 13, eabf4969.	5.8	5
430	Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4428-4437.	0.9	5
431	Genotoxicity of pancreatic chemical carcinogens to propagable cultured normal pancreatic epithelial cells. <i>Experimental and Molecular Pathology</i> , 1990, 53, 203-210.	0.9	4
432	Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap?. <i>Journal of the National Cancer Institute</i> , 2007, 99, 826-827.	3.0	4

#	ARTICLE	IF	CITATIONS
433	Gene Expression Profiling of Adenosine Triphosphate-Binding Cassette Transporters in Response to K-ras Activation and Hypoxia in Human Pancreatic Cancer Cell Cultures. <i>Pancreas</i> , 2009, 38, 85-93.	0.5	4
434	Preparing for tomorrow: Molecular diagnostics and the changing nonsmall cell lung cancer landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 2-10.	0.7	4
435	A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e41-e47.	1.1	4
436	Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC). <i>BMC Cancer</i> , 2018, 18, 429.	1.1	4
437	EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. <i>Lung Cancer</i> , 2020, 145, 144-151.	0.9	4
438	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2594-2594.	0.8	4
439	Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. <i>Journal of Molecular Biology</i> , 2021, 433, 167294.	2.0	4
440	From Solo in the Silo to Strategic Training Programs. <i>CBE Life Sciences Education</i> , 2016, 15, 1e1.	1.1	3
441	An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2248-2252.	0.5	3
442	Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21127-e21127.	0.8	3
443	A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1036-1036.	0.8	3
444	Phase II study of PX-866 in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2053-2053.	0.8	3
445	Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7521-7521.	0.8	3
446	The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10522-10522.	0.8	3
447	Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage 3 non-small cell lung cancer: safety and efficacy. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100251.	0.6	3
448	Reprint of Introduction to 2021 WHO Classification of Thoracic Tumors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 337-340.	0.5	3
449	Molecular Prognostication of Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2013, 25, 4-7.	0.4	2
450	Predictive Versus Prognostic Value of Lung Adenocarcinoma Classification. <i>Journal of Clinical Oncology</i> , 2015, 33, 225-226.	0.8	2

#	ARTICLE	IF	CITATIONS
451	The eighth TNM classification for lung cancer—What is next?. <i>Lung Cancer</i> , 2018, 121, 97-98.	0.9	2
452	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1009.	1.7	2
453	Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. <i>Clinical Trials</i> , 2020, 17, 202-211.	0.7	2
454	Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21123-e21123.	0.8	2
455	Abstract B282: The PLK-4 inhibitor CFI-400945 reduces tumor growth in patient-derived pancreatic xenografts.. , 2013, , .		2
456	Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for <i>ALK</i> gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8096-8096.	0.8	2
457	Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 11060-11060.	0.8	2
458	Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20091-e20091.	0.8	2
459	Upfront next generation sequencing in NSCLC: A publicly funded perspective.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12062-12062.	0.8	2
460	Expression of protein disulfide isomerase in cultured rat liver epithelial cells is unrelated to the growth inhibitory effect of TGF- $\beta$ 1. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 478-482.	1.0	1
461	Enhanced Expression of Alpha-Fetoprotein Gene in Cultured Rat Liver Epithelial Cells Treated with N-Methyl-N'-Nitrosoguanidine. <i>Pathobiology</i> , 1993, 61, 25-30.	1.9	1
462	Genomic and Cellular Pathology of Lung Cancer. <i>Current Respiratory Medicine Reviews</i> , 2011, 7, 313-322.	0.1	1
463	Reply to C.G. Azzoli et al and C. Chouaid et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3578-3579.	0.8	1
464	Pulmonary Adenocarcinoma—Pathology and Molecular Testing. , 2019, , 13-33.		1
465	Point-of-Care Spirometry Identifies High-Risk Individuals Excluded from Lung Cancer Screening. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1473-1477.	2.5	1
466	Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8547-8547.	0.8	1
467	zo2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. <i>International Journal of Cancer</i> , 1999, 83, 349-358.	2.3	1
468	Genomic Pathology of Lung Cancer. , 2013, , 1-46.		1

#	ARTICLE	IF	CITATIONS
469	Abstract 4912: Systematic, comparative network analysis on non-small cell lung cancer. <i>Cancer Research</i> , 2012, 72, 4912-4912.	0.4	1
470	Plasma osteopontin and the prognosis of pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11109-11109.	0.8	1
471	A targeted intervention to improve awareness to molecular testing in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6547-6547.	0.8	1
472	Lung cancer in never-smokers from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8099-8099.	0.8	1
473	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 459-459.	0.8	1
474	Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20667-e20667.	0.8	1
475	Characterizing the last holdouts. <i>Oncotarget</i> , 2017, 8, 12542-12543.	0.8	1
476	Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11057-11057.	0.8	1
477	Willingness of patients to provide biologic samples for pharmacogenomic testing.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6543-6543.	0.8	1
478	Abstract 1184: Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patient-derived xenografts (PDX) of non-small cell lung cancer (NSCLC). , 2014, , .		1
479	TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3050-3050.	0.8	1
480	Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway. , 2020, , .		1
481	Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100259.	0.6	1
482	Molecular testing and patterns of treatment in patients with NSCLC: An IASLC analysis of ASCO CancerLinQ Discovery Data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9128-9128.	0.8	1
483	Primary Pulmonary Primitive Neuroectodermal Tumor (PNET). <i>Pathology Research and Practice</i> , 2001, 197, 121-122.	1.0	0
484	Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients. <i>Personalized Medicine</i> , 2008, 5, 325-329.	0.8	0
485	Carcinoma-Associated Fibroblasts in Lung Cancer. , 2009, , 193-215.		0
486	Fibroblast Growth Factor Inhibitors. <i>Journal of Thoracic Oncology</i> , 2010, 5, S457.	0.5	0

#	ARTICLE	IF	CITATIONS
487	Response to Yamamoto etÂal.. Journal of Thoracic Oncology, 2016, 11, e129-e130.	0.5	0
488	Role of the Extracellular Matrix in Tumor Stroma: Barrier or Support?. , 2017, , 77-112.		0
489	Modeling Drug Resistance in PDX Models. Molecular and Translational Medicine, 2017, , 115-126.	0.4	0
490	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.		0
491	Cover Image, Volume 40, Issue 6. Medicinal Research Reviews, 2020, 40, ii.	5.0	0
492	Immune Resistance Interrogation Study (IRIS): A prospective comprehensive multi-omic analysis in patients with intrinsic and acquired resistance to immunotherapy.. Journal of Clinical Oncology, 2021, 39, TPS2679-TPS2679.	0.8	0
493	The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.. Journal of Clinical Oncology, 2021, 39, 3126-3126.	0.8	0
494	Stratification and management of patients ineligible for lung cancer screening. Respiratory Medicine, 2021, 188, 106610.	1.3	0
495	A6-06: Integrative genomic and gene expression analysis of NSCLC identifies subtype-specific signatures of pathway disruption. Journal of Thoracic Oncology, 2007, 2, S328.	0.5	0
496	Abstract 5566: Phosphoproteomic profiling of Met / K-Ras signaling in colorectal cancer by label-free LTQ-Orbitrap mass spectrometry. , 2010, , .		0
497	Abstract 3133: In vitro modeling of human pancreatic duct epithelial cell transformation. , 2010, , .		0
498	Abstract 1091: The role for retinoblastoma-like p130 (RBL2) and DNA damage response in human pancreatic cancer cells. , 2010, , .		0
499	Abstract 5049: Functional significance ofL1CAMin non-small cell lung cancer. , 2010, , .		0
500	Abstract 1998: Asparseprognostic gene signature for stage IB and II patients with completely resected non-small cell lung cancer. , 2010, , .		0
501	Abstract 2431: Inhibition of metastasis through therapeutic targeting of focal adhesion kinase (FAK) in pancreatic cancer. , 2011, , .		0
502	Abstract 5097: Proteomic characterization of non-small cell lung cancer (NSCLC): Discovery and validation of NSCLC protein signatures and signaling networks. , 2011, , .		0
503	Abstract 1404: L1CAM in non-small-cell lung carcinoma. , 2011, , .		0
504	Abstract 4919: Multiplexed EGFR signaling pathway analysis in FFPE tissue using quantitative mass spectrometry. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
505	Abstract A29: Genomic alteration of E2F/Rb activates EZH2 in small cell lung cancer. <i>Clinical Cancer Research</i> , 2012, 18, A29-A29.	3.2	0
506	Abstract B34: Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012, 18, B34-B34.	3.2	0
507	Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 240-240.	0.8	0
508	Abstract 1232: Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. , 2012, , .		0
509	Abstract 5069: Genomic profiles of primary non-small cell lung cancer (NSCLC) xenograft tumors identify distinct gene signatures associated with histological subtypes. , 2012, , .		0
510	Abstract 5127: Characterization of lung cancers by integrated genomic and proteomic analysis. , 2012, , .		0
511	Abstract 4210: Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. , 2012, , .		0
512	Abstract 4805: Distinctive phospho-proteome signatures in non-small cell lung carcinoma tumors. , 2012, , .		0
513	Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7586-7586.	0.8	0
514	Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1535-1535.	0.8	0
515	Phase II study of PX-866 in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2051-2051.	0.8	0
516	Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 196-196.	0.8	0
517	Performance of a prognostic genomic signature for early-stage NSCLC in matched fresh frozen and RNA-stabilized tissue.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7532-7532.	0.8	0
518	Clinical impact of <i>EGFR</i> mutation fraction and tumor cellularity in <i>EGFR</i> mutation positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19077-e19077.	0.8	0
519	Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7516-7516.	0.8	0
520	ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22042-e22042.	0.8	0
521	Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7517-7517.	0.8	0
522	Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19032-e19032.	0.8	0

#	ARTICLE	IF	CITATIONS
523	Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19031-e19031.	0.8	0
524	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
525	Abstract IA10: Molecular testing to personalized EGFR and ALK inhibitor therapies in lung cancer.. Clinical Cancer Research, 2014, 20, IA10-IA10.	3.2	0
526	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Center experience.. Journal of Clinical Oncology, 2014, 32, 3572-3572.	0.8	0
527	Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, 6595-6595.	0.8	0
528	Canadian ALK (CALK): A multicenter, prospective study of concurrent ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in NSCLC.. Journal of Clinical Oncology, 2014, 32, 8070-8070.	0.8	0
529	Abstract 4800: Heterogeneity of cancer associated fibroblasts in non-small cell lung cancer is defined by the level of collagen gel contraction activity. , 2014, , .		0
530	Abstract 1553: Rho guanine nucleotide exchange factor (ARHGEF) 10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. , 2014, , .		0
531	Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2015, 33, e19006-e19006.	0.8	0
532	<i>EGFR</i> mutations in NSCLC: Does ethnicity influence outcomes?. Journal of Clinical Oncology, 2015, 33, e17633-e17633.	0.8	0
533	Abstract A102: Combination treatment with hypoxia-activated prodrug TH-302 and radiation reduce pancreatic tumor initiating cells and tumor growth in patient-derived xenografts. , 2015, , .		0
534	Abstract A106: BRCA mutation sensitizes pancreatic tumors to treatment with cisplatin. , 2015, , .		0
535	Abstract 1822: Proteome signatures distinguish lung cancer subtypes, define metabolism states, and have prognostic impact. , 2015, , .		0
536	Abstract B2-01: Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. , 2015, , .		0
537	Abstract A2-49: Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. , 2015, , .		0
538	Taking action on actionable mutations: a French initiative on universality in precision cancer care. Translational Cancer Research, 2016, 5, S35-S39.	0.4	0
539	Abstract A64: Mast cell expressed Fc̳R beta subunit (MS4A2) is prognostic in lung adenocarcinoma. , 2017, , .		0
540	A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 332-332.	0.8	0

#	ARTICLE	IF	CITATIONS
541	Patientsâ€™ willingness to pay for blood-based <i>EGFR</i> <i>T790M</i> testing: Results from a Canadian validation study of circulating DNA <i>T790M</i> testing.. Journal of Clinical Oncology, 2017, 35, e18329-e18329.	0.8	0
542	Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9024-9024.	0.8	0
543	Use of a marketing plan for recruitment to a lung cancer screening study.. Journal of Clinical Oncology, 2017, 35, 1548-1548.	0.8	0
544	The effect of prior smoking history on the molecular profile of <i>EGFR</i> mutant ( <i>EGFRm</i> ) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 8533-8533.	0.8	0
545	Abstract 2443: Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma. , 2018, , .		0
546	Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in <i>EGFR</i> -mutated lung adenocarcinoma (LUAD).. Journal of Clinical Oncology, 2019, 37, 3110-3110.	0.8	0
547	Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.. Journal of Clinical Oncology, 2019, 37, e20594-e20594.	0.8	0
548	Methylation profiling of <i>EGFR</i> mutant primary and metastatic lung cancer with brain metastasis.. Journal of Clinical Oncology, 2019, 37, e20574-e20574.	0.8	0
549	Abstract 3378: Systematic pharmacogenomic analysis of large patient derived xenografts data. , 2019, , .		0
550	Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, e21092-e21092.	0.8	0
551	Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2020, 38, e21080-e21080.	0.8	0
552	A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006).. Journal of Clinical Oncology, 2020, 38, TPS9079-TPS9079.	0.8	0
553	Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC.. Journal of Clinical Oncology, 2020, 38, 3084-3084.	0.8	0
554	Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers.. Journal of Clinical Oncology, 2020, 38, 3571-3571.	0.8	0
555	Abstract 4550: Correlations between tumor mutation burden, inflammatory profile and histological characteristics of tumor microenvironment in early-stage squamous cell lung carcinoma. , 2019, , .		0
556	Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.. Journal of Clinical Oncology, 2022, 40, 3039-3039.	0.8	0